Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification
| Autor: | Vanderlei Segatelli, Roberto Carmagnani Pestana, Francinne T. Tostes, Donato Callegaro, Italo Fernandes |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Colorectal cancer Prior diagnosis Pembrolizumab Antibodies Monoclonal Humanized B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Text mining Partial response PD-L1 medicine Humans biology business.industry Gastroenterology Anal Squamous Cell Carcinoma Anus Neoplasms medicine.disease Immune checkpoint Oncology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Cancer research biology.protein Female 030211 gastroenterology & hepatology business |
| Zdroj: | Clinical Colorectal Cancer. 20:350-353 |
| ISSN: | 1533-0028 |
| Popis: | We report the case of a 44-year-old female with a prior diagnosis of Sjögren's syndrome who was treated for metastatic anal squamous cell carcinoma with second-line pembrolizumab and has achieved a sustained partial response after a follow-up of 13 months. Comprehensive genomic profiling was remarkable for PD-L1 and PD-L2 amplification and a high tumor mutational burden (19 mutations per megabase). To the best of our knowledge, we present the first report to correlate PD-L1 and PD-L2 amplification with good outcomes of immune checkpoint inhibition in metastatic anal squamous cell carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect